Discover CGM with engagement*1,2 and insights†3,4.
Help empower your patients and achieve better clinical outcomes*1,5,6.
CGM = continuous glucose monitor(ing)
FreeStyle Libre CGMs deliver real-time glucose data.
- View patients’ complete glycemic profiles anytime‡, enabling more informed treatment decisions*7.
- Patients can respond faster to glucose changes, helping to avoid hypoglycemia.
- Significantly lowers A1C*6,§8 without fingersticksǁ.
See the full picture3 without the pain and hassle of fingersticksǁ.
CGM provides a more complete picture of where a patient's glucose is and where it is going, so they can make more informed decisions.
BGM measures a single point in time.
CGM provides glucose readings every minute.
For illustrative purposes only. Not actual patient data.
BGM = blood glucose monitor(ing)
Increase in time in range can help your patients improve A1C9.
A1C provides a broad snapshot reflecting average glucose over 2–3 months9,10.
Time in range (TIR) is the percentage of time your patient spends in a pre-set glucose target range9.
- TIR report includes time above range, time in target range, and time below range11,12.
- TIR offers context for A1C by allowing you to quickly assess the patient’s glucose control.
See how FreeStyle Libre systems can help all people with diabetes.
Discover how FreeStyle Libre systems can support a wide range of patients.
- Insulin-using patients*13,¶#14
- Non-insulin–using patients with T2D¶#14
- Adults at high risk of hypoglycemia*,**1,5
T2D = Type 2 diabetes
The FreeStyle Libre 3 system includes the Libre 3 Plus sensor, Libre 3 sensor, Libre 3 app, Libre app, and the Libre 3 reader.
The FreeStyle Libre 2 system includes the Libre 2 Plus sensor, Libre 2 sensor, Libre 2 app, Libre app, and the Libre 2 reader.
FreeStyle Libre 3 system is cleared to be used by children 4 years and older with Libre 3 sensor and 2 years and older with Libre 3 Plus sensor.
FreeStyle Libre 2 system is cleared to be used by children 4 years and older with Libre 2 sensor and 2 years and older with Libre 2 Plus sensor.
The product images are for illustrative purposes only. Not actual patient data.
Medicare and other payor criteria may apply.
The FreeStyle Libre systems apps are only compatible with certain mobile devices and operating systems. Please check the Support section of our website for more information about device compatibility before using the apps. Use of the FreeStyle Libre systems apps may require registration with LibreView.
* Study was performed with the outside US version of the FreeStyle Libre 14 day system. Data is applicable to FreeStyle Libre 2 and FreeStyle Libre 3 systems, as feature sets are similar as FreeStyle Libre 14 day system, excluding alarms.
† The LibreView data management software is intended for use by both patients and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis, and evaluation of historical glucose meter data to support effective diabetes management. The LibreView software is not intended to provide treatment decisions or to be used as a substitute for professional healthcare advice.
‡ 60-minute warm-up required when starting the sensor.
§ Study was performed with the outside US version of the FreeStyle Libre 2 system. Data is applicable to FreeStyle Libre 3 system, as feature sets are similar.
ǁ Fingersticks are required if your glucose alarms and readings do not match symptoms or when you see Check Blood Glucose symbol during the first twelve hours.
¶ Study was performed with the US version of the FreeStyle Libre 14 day system. Data is applicable to FreeStyle Libre 2 and FreeStyle Libre 3 systems, as feature sets are similar as FreeStyle Libre 14 day system, excluding alarms.
# Observational study with mean A1C levels of 10.1% at baseline.
** REPLACE trial: a randomized, controlled trial to evaluate the impact of FreeStyle Libre glucose monitoring system (n=149) on HbA1c in people with type 2 diabetes (T2D) taking multiple daily doses of insulin at 6 months compared to blood glucose monitoring (BGM;n=75).
References: 1. Haak, Thomas, et al. "Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-treated Type 2 Diabetes: a Multicentre, Open-label Randomised Controlled Trial." Diabetes Therapy 8, no. 1 (2017): 55–73. https://doi.org/10.1007/s13300-016-0223-6. 2. Campbell, Fiona M., et al. “Outcomes of Using Flash Glucose Monitoring Technology by Children and Young People With Type 1 Diabetes in a Single Arm Study." Pediatric Diabetes 19, no. 7 (2018): 1294–1301. https://doi.org/10.1111/pedi.12735. 3. Unger, Jeff, Pamela Kushner, and John E. Anderson. “Practical Guidance for Using the FreeStyle Libre Flash Continuous Glucose Monitoring in Primary Care.” Postgraduate Medicine 132, no. 4 (2020): 305–313. https://doi.org/10.1080/00325481.2020.1744393. 4. Data on file. Abbott Diabetes Care, Inc. 5. Bolinder, Jan, et al. “Novel Glucose-sensing Technology and Hypoglycaemia in Type 1 Diabetes: a Multicentre, Non-masked, Randomised Controlled Trial.” The Lancet 388, no. 10057 (2016): 2254–2263. https://doi.org/10.1016/S0140-6736(16)31535-5. 6. Evans, Mark, Zoë Welsh, and Alexander Seibold. “Reductions in HbA1c With Flash Glucose Monitoring Are Sustained for up to 24 Months: A Meta-analysis of 75 Real-world Observational Studies.” Diabetes Therapy 13, no. 6 (2022): 1175–1185. https://doi.org/10.1007/s13300-022-01253-9. 7. Fokkert, Marion, et al. "Improved Well-Being and Decreased Disease Burden After 1-Year Use of Flash Glucose Monitoring (FLARE-NL4)." BMJ Open Diabetes Research & Care 7, no. 1 (2019): e000809. https://doi.org/10.1136/bmjdrc-2019-000809. 8. Leelarathna, Lalantha, et al. “Intermittently Scanned Continuous Glucose Monitoring for Type 1 Diabetes.” New England Journal of Medicine 387, no. 16 (2022): 1477–1487. https://doi.org/10.1056/nejmoa2205650. 9. Battelino, Tadej, et al. "Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range." Diabetes Care 42, no. 8 (2019): 1593–1603. https://doi.org/10.2337/dci19-0028. 10. Hirsch, Irl. B. and Eugene E. Wright Jr. “Using Flash Continuous Glucose Monitoring in Primary Practice.” Clinical Diabetes 37, no. 2 (2019): 150–161. https://doi.org/10.2337/cd18-0054. 11. FreeStyle Libre 2 User's Manual. 12. FreeStyle Libre 3 User's Manual. 13. Kröger, Jens, Peter Fasching, and Hélène Hanaire. “Three European Retrospective Real-World Chart Review Studies to Determine the Effectiveness of Flash Glucose Monitoring on HbA1c in Adults with Type 2 Diabetes.” Diabetes Therapy 11, no. 1 (2020): 279–291. https://doi.org/10.1007/s13300-019-00741-9. 14. Wright, Eugene E., et al. "Use of Flash Continuous Glucose Monitoring Is Associated With A1c Reduction in People With Type 2 Diabetes Treated With Basal Insulin or Noninsulin Therapy." Diabetes Spectrum (2021): ds200069. https://doi.org/10.2337/ds20-0069.
ADC-42701 v4.0
Important Safety Information
Failure to use FreeStyle Libre systems as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury. If glucose reading and alarms (if enabled) do not match symptoms or expectations, use a fingerstick value from a blood glucose meter for treatment decisions. Get medical attention when appropriate. Abbott Customer Service at 855-632-8658 or visit FreeStyleLibre.us for safety info.
The product images are for illustrative purposes only.
The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott. Other trademarks are the property of their respective owners.
No use of any Abbott trademark, trade name, or trade dress in this site may be made without prior written authorization of Abbott Laboratories, except to identify the product or services of the company.
This website and the information contained herein is intended for use by residents of the United States.
ADC-45115 v23.0
